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PL-04
SETTING THE STANDARDS IN HPB 
SURGERY
R. Padbury
Flinders Medical Centre, Bedford Park, SA, Australia
Quality care can be diffi cult to defi ne although most surgeons 
would have a concept of what it means to them. It is impor-
tant to consider quality from a patient perspective and then 
describe the various domains.
Safety: The avoidance or reduction to minimum levels of 
actual or potential harm from healthcare.
Effectiveness: Care intervention or action achieves desired 
outcomes.
Appropriateness: Care intervention or action is relevant to 
patient needs and based on best evidence.
Effi ciency: Achieving desired outcomes with most effective 
use of resources
Accessibility: Ability to meet demand.
Acceptability: Care delivered meets cultural, social and 
physical needs of the patient.
Attention should be directed at all links in the process to 
deliver care. Defects at any stage will have clinical outcome 
consequences. It is important to account for many different 
members of the care team to ensure high quality end produc-
tion. It is also important to focus on the requirements of 
patients who do not have surgical intervention or at least not 
potentially curative surgery. In HPB disease this is particu-
larly relevant to HCC in cirrhotics and pancreatic cancer.
To monitor and improve quality requires a balanced set of 
measures. These should be aligned with the domains of 
quality and constitute a mixture of process and outcome.
A number of studies have demonstrated that omissions in 
healthcare are a signifi cant quality defect and recognition of 
this requires system design to signifi cantly reduce this 
problem.
PL-05
SURGICAL ACCESS AND INSTRUMENT 
DESIGNS
N. O’Rourke
Abstract not available at time of publication.
PL-06
LAPAROSCOPIC SURGERY FOR GALL 
BLADDER CANCER
X. J. Cai, H. Yu, X. Liang and Y. F. Wang
Department of Surgery, Sir Run Run Shaw Hospital, 
Zhejiang University, Hangzhou, P.R.China
Introduction: Minimal invasion is the greatest benefi t of 
laparoscopic liver resection (LLR). With the development of 
surgical techniques, laparoscopic liver resection had been 
used in treatment for malignant liver tumor including hepa-
tocellular carcinoma, cholangiocarcinoma and metastatic 
liver cancer. We reported the experience of laparoscopic liver 
resection for liver malignancy.
Methods: Patients undergoing laparoscopic liver resection 
for malignant liver tumor between August 1998 and 
December 2010 in our center had been reviewed. Liver tran-
section was performed using laparoscopic Peng’s multifunc-
tional operative dissector, and tumor was placed in a plastic 
bag and extracted through a small incision of 3–5 cm. 
Surgical features, postoperative courses and clinical out-
comes were achieved from medical record and computer 
database.
Results: Total of 86 patients (32 female and 54 male) had 
undergone laparoscopic liver resection for malignant pathol-
ogy including 62 hepatocellular carcinoma, 10 hepatic 
metastases, 6 gallbladder cancer and 8 others malignant dis-
eases. Mean age was 57 years old. Procedure included local 
resections, left lateral segmentectomy, left lobectomy. 6 
patients had to convert to open liver resection. Mean intra-
operative blood loss was 685 ml, and mean operating time 
was 171 min. 4 complication occurred postoperatively 
including 1 bleeding, 1 liver disfunction, 2 pulmonary infec-
tions. The patient with bleeding had reoperated and all the 
four patients recovered uneventfully. There is no death.
Conclusions: Laparoscopic surgery can be a potential and 
effective option for liver malignancy.
PL-07
ROBOTIC HEPATO-BILIO-PANCREATIC 
SURGERY
W.-J. Lee
Division of HBP, Department of Surgery, Yonsei University 
College of Medicine, Yonsei University Health System, 
Seoul, Korea
Our hospital has started laparoscopic cholecystectomy in 
1991, and after then many surgeons have been trained in the 
era of laparoscopic and minimally invasive surgery. Since 
then numerous procedures have been applied for a laparo-
scopic surgery, and many patients have been benefi ted as a 
result. We have performed the fi rst automated surgery in 
Korea using Automated Endoscopic System for Optimal 
Positioning (AESOP) in June, 1996.
With the help of Inbae Yoon’s (a 1961 graduate of our 
medical school) inspiration and donation, our hospital has 
started “IB Yoon Multi-Specialty Endoscopic Research & 
Training Center” in 1998. As we started the robotic surgery 
we have change the name to “Severance Robotic and 
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Minimally Invasive Surgery Center” in March 2005. These 
infrastructures enables us the expansion of laparoscopic 
surgery and inspires many surgeons to understand principles 
and equipments of laparoscopic and robotic surgery. We 
performed the fi rst robotic surgery using da Vinci system in 
July, 2005. During 5 and half years after introducing the da 
Vinci surgical system in 2005 we have performed more than 
5000 cases of robotic surgery successfully. With collabora-
tion between medicine and robotic engineering company, we 
are developing our own version of Korean robotic system.
In conventional laparoscopic surgery, limited motion of 
laparoscopic instruments, 2-D surgical fi eld, and unstable 
surgical view resulted from unnecessary movement of lapa-
roscope (shaking surgical fi eld) by assist surgeons, magnify-
ing tremor of laparoscopic instrument, and unexpected 
movement of laparoscopic instrument by another assist-sur-
geon can accidentally produce inappropriate environment for 
safe laparoscopic surgery. To the contrary, stable 3-D surgi-
cal fi eld provided by robot surgical system, wrist like move-
ment of instrument, stationary holding of fourth arm 
movement (to replace the role of assistant surgeon in lapa-
roscopic surgery) seems to produce very appropriate surgical 
environment for safe laparoscopic HBP surgery. Therefore, 
robot is thought to be very appropriate for function-preserv-
ing minimal invasive HBP surgery.
Among 65000 robotic operation (including Kangnam 
Severance Hospital), the number of HBP robotic surgery is 
about only 100 cases, but is slowly growing. After we have 
started with robotic cholecystectomy (two cases) for initial 
experience, we have expanded our indication for robotic 
HBP surgery. We started robotic choledocal cyst operation in 
late 2005 and until now have performed 12 cases without 
conversion. In 2007, we have started robotic liver resection 
and until now we have performed 25 cases of robotic liver 
resection including 3 right lobectomy. In June of 2007, we 
started robotic pancreatic cyst enucleation and until now we 
have performed 48 cases of robotic pancreatic surgery 
including 30 distal pancreatectomy, 5 central pancreatectomy 
and 7 PPPD (pylorus preserving pancreato duodenectomy). 
As we have a good result of laparoscopic simple cholecys-
tectomy and lymph node dissection including aortocaval 
lymph node (#16) for early gall bladder cancer less than T2 
lesion, we have applied this technique using robotic system 
and we have performed 12 robotic cases of cholecystectomy 
and lymph node dissection for GB cancer less than T2 lesion 
without recurrences until now. Recently we have applied this 
minimally invasive technique (simple cholecystectomy and 
lymph node dissection including #16) even for open surgery 
for early GB cancer (less than T2) and we can get very good 
result.
However, it is still obscure if current robotic surgical 
system could be popular in near future. Expensive high cost, 
longer operation time, and already advanced conventional 
laparoscopic techniques are all intermingled facts we are 
facing. Minimally invasive surgery has replaced conven-
tional open surgery in most surgical fi eld. The ultimate goal 
of robot surgery and conventional laparoscopic surgery are 
thought to be same, because both two surgical approaches 
are belong to the same category of minimally invasive 
surgery. Therefore, end clinical results may be similar to 
each. Currently, surgeons need to be more fl exible in choos-
ing surgical options for successful minimally invasive 
surgery. It may depend on surgeons’ experiences, techniques, 
preference, patients’ economic status, patients’ general health 
condition, disease severity, and so forth. It may not be impor-
tant whether surgeons can do robot surgery or not, but it is 
more important whether surgeons can provide the patients 
with safe minimally invasive surgery.
PL-08
NAVIGATION IMAGING SYSTEMS 
AND SURGERY
G. V. Rao
Abstract not available at time of publication.
PL-09
INTRA-CORPOREAL 
MICRO INSTRUMENTS 
AND NANOTECHNOLOGY
G. Maddern
University of Adelaide, Discipline of Surgery, The Queen 
Elizabeth Hospital, Adelaide, SA, Australia
Nano-medicine is the application of nanotechnology to 
achieve breakthroughs in healthcare. It exploits the improved 
and often novel physical, chemical and biological properties 
of materials at the nano-meter scale and has the potential to 
enable early detection and prevention, and to improve diag-
nosis, treatment and followup of a number of conditions. 
Nanotechnology entails the manufacturing and manipulation 
of matter at a scale ranging from single atoms to micron-
sized objects.
Medical applications of nanotechnology include nanovec-
tors, nano-electrotransducers, control of cell movement, 
magnetic drug delivery, MRI contrast agents, nanohyperther-
mic ablation, antibacterial, electro-chemotherapy, nano-
bio-generators, nano-bioi-sensors and nano-scaffolds.
Currently nano-medicine is at the fi rst generation stage of 
nanotechnology but progress has now reached the threshold 
of the second generation (active nanomaterials) with early 
clinical trials, currently in the fi eld of controlled drug deliv-
ery and cell therapies.
Substantial progress has been made in technologies and 
devices for wireless electro-chemotherapy and electro-stim-
ulation therapies but further R&D is needed as well as pre-
clinical safety and effi cacy studies.
As technology has progressed, the size of laparoscopic 
instruments has diminished in an attempt by surgeons to 
minimize the trauma induced by their procedures. Traditional 
laparoscopy requires cuts of 11 mm diameter to be able to 
insert certain instruments, such as the clip applicator (used 
to occlude blood vessels and ducts). Once the more advanced 
laparoscopic surgeons started stitching these structures to 
intracorporeal suturing, the need for the 11 mm hold dimin-
ished to 5 mm and subsequently 3 mm diameter instruments 
are now being used.
However, the disadvantages remain of prolonged opera-
tive times in patients with higher body weights, peritoneal 
adhesions, chronic infl ammation and gall-bladder wall thick-
ening (in cholecystectomy) have been cited as obstacles to 
micro-laparoscopic surgery in various studies. Although pos-
sible, clinical benefi ts are yet to be established.
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PL-10
EUS GUIDED INTERVENTIONAL 
TECHNIQUES IN HPB DISORDERS
D. W. Seo
Department of Gastroenterology, Asan Medical Center, 
University of Ulsan Medical College, Seoul, Korea
Endoscopic ultrasound (EUS) has made a tremendous leap 
from imaging modality to histological diagnosis and thera-
peutic intervention during last 30 years. With the advent of 
linear-array echoendoscope, it became possible to trace 
needle tract under ultrasound and to do EUS-guided fi ne 
needle aspiration (EUS-FNA). EUS-FNA can give us histo-
logical diagnosis of HPB lesions such as biliary tumor, 
pancreatic tumor, hepatoduodenal or peripancreatic lymph-
adenopathy and left hepatic mass. EUS-guided interventions 
are also applied to HPB disorders using various modifi ca-
tions of EUS-FNA technology. EUS-guided biliary drainage 
(EUS-BD) is one of interventional applications for patients 
with obstructive jaundice which is not amenable by conven-
tional percutaneous transhepatic biliary drainage or endo-
scopic biliary drainage. After locating the tip of echoendoscope 
in the duodenum or stomach, EUS-guided choledochoduo-
denostomy or hepaticogastrostomy can be performed by 
placing plastic stent or covered self expandable metal stent. 
EUS-BD also includes rendevouz procedures in which a 
guidewire can be passed through the bile duct under EUS 
and fl uoroscopic view via transgastric route or transduodenal 
route. EUS-guided gallbladder drainage is one of EUS-
guided interventions under investigation in patients with 
acute cholecystitis as a bridge therapy before surgery. 
Pancreatic pseudocyst is now managed effectively and safely 
with EUS-guided approach. Since most of pseudocysts 
develop near the gastroduodenal wall or peripancreatic area, 
EUS can delineate the lesion and several drainage stents can 
be placed successfully under EUS and fl uoroscopic guid-
ance. This technique is also applied for the management of 
postoperative pancreatic fl uid collections. EUS-guided 
ethanol lavage with/without paclitaxel injection has been 
tested for the treatment of cystic tumors of the pancreas, with 
complete resolution of cystic tumor being observed in up to 
70~80% of patients. Ethanol injection is also tried for the 
treatment of solid neuroendocrine tumors of the pancreas. 
EUS-guided local ablation therapies such as radiofrequency 
ablation, photodynamic therapy, and brachytherapy are also 
under investigation. EUS-guided drainage or injection tech-
nologies are rapidly expanding fi eld and may have the poten-
tial to reshape our future therapeutic approach of HPB 
disorders.
PL-11
ROLE OF RADIOFREQUENCY 
ABLATION IN THE TREATMENT OF 
HEPATOCELLULAR CARCINOMA: 
EXPERIENCE OF A CANCER CENTER IN 
CHINA
M.-S. Chen
Department of Hepatobiliary Surgery, Cancer Center, Sun 
Yat-sen University, Guangzhou, P.R. China
Radiofrequency ablation (RFA) has become an important 
treatment for hepatocellular carcinoma (HCC). The good 
candidates of RFA are patients with HCC at early stage 
(solitary ≤5 cm in diameter or ≤3 nodules, ≤3 cm in diam-
eter). Several clinical trials have shown RFA was as effective 
as resection in the treatment of small HCC. Until now, RFA 
has been widely used as a radical treatment for small HCC. 
RFA also plays an important role in the multidisciplinary 
treatment of HCC and usually combines with other therapies 
such as resection, vascular intervention, intra-tumor ethanol 
injection, radiotherapy, chemotherapy, targeted drug therapy, 
biological immune therapy. In this study, we will introduce 
our experience of RFA in the treatment of HCC in a cancer 
center in China.
PL-12
HIFU – CURRENT STATUS
W. Y. Lau
The Chinese University of Hong Kong, Shatin, Hong Kong 
SAR
Highly-intensity focused ultrasound (HIFU) is a technology 
that uses highly-energy ultrasonic wave in the frequency 
range of 0.8–3.5 MHz, which is projected and focused on a 
point inside the body of a patient for treatment, sparing other 
normal tissues.
Second-generation of HIFU uses 8 emitters in a circle, 
with each emitter bearing less energy which travel through 
a different part of the skin and other underlying structures, 
thus avoiding discomfort or burn to the non-tumorous tissues. 
This makes the treatment well-tolerated and eliminates the 
need for general anesthesia. Ultrasonic energy ablates the 
tumor by heat and a physical/mechanical effect. Tumor local-
ization is usually done by ultrasound or MRI. Each session 
usually lasts about 90 minutes. As most patients cannot toler-
ate long immobilization, multiple sessions are needed. There 
is no need for post-treatment analgesics and patient usually 
can go home after treatment and continue with normal daily 
life.
The use of HIFU has been used in liver, kidney, pancreatic 
and prostate cancer, and in uterine fi broid. Survival benefi ts 
was demonstrated when HIFU was combined with TACE 
when compared with TACE alone for unresectable liver 
cancer.
HIFU is generally very safe, and it is radiation free. The 
main limitations of HIFU are (1) it is suitable only for treat-
ment in regions that are not surrounded by bony structures; 
(2) it is unsuitable for widespread disease.
Conclusion: HIFU is a new, well-tolerated non-invasive 
treatment for various types of benign and malignant diseases. 
Its effectiveness has only been shown in selected patients.
PL-13
STEREOTACTIC RADIOTHERAPY AND 
4D IMAGING
I. W. T. Porter
William Buckland Radiotherapy Centre, The Alfred, 
Melbourne, Australia
Introduction: Stereotactic conformal radiotherapy is a new 
technological advance making it possible to deliver high 
doses of radiation therapy precisely to small tumors whilst 
preserving function in critical structures surrounding the 
index lesions. Patients with oligometastatic disease many not 
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always be surgical candidates due to medical co-morbidities, 
tumor size or location. Stereotactic radiotherapy may be a 
therapeutic option with potentially a lower morbidity profi le. 
Four dimensional imaging with respiratory gaiting provides 
a technological building-block to facilitate this technique. 
State of the art application of hepatic stereotactic conformal 
radiotherapy will be discussed.
Conclusion: High dose focal radiation can provide potential 
gains in survival and palliation with attenuated morbidity for 
selected patients with oligometastatic disease.
PL-14
IRREVERSIBLE ELECTROPORATION 
(IRE)
G. Maddern
University of Adelaide, Discipline of Surgery, The Queen 
Elizabeth Hospital, Adelaide, SA, Australia
The pursuit of novel non-thermal ablative techniques has led 
to recent reports of electroporation to active tumor destruc-
tion. Several microsecond to millisecond long electric pulses 
are delivered to the target tissue to induce permanent cell 
membrane permeability and cell death. The mechanism 
through which the cell membrane is permeabilized is not yet 
fully understood. Currently it is thought to be related to the 
formation of nano-scaled defects or pores in the cell mem-
brane (poration). It appears to have no effect on surrounding 
cell structures, delivering a complete hepatocyte cell death 
within the ablation zone with a narrow transition between the 
ablation zone and the surrounding undamaged tissue.
Current systems that are commercially available comprise 
a high voltage generator controlling voltage, current, pulse 
length intervals and number combined with probes for deliv-
ering energy into tissues. The energy is discharged via mono- 
or bipolar probes with an active tip of a few centimeters. 
Currently report in use in 20 countries worldwide, only 
reported in conference proceedings with published human 
data on only 6 patients with renal cell carcinoma. It remains 
new, interesting and unproven.
PL-15
THERAPEUTIC EFFECT OF 
TRANSARTERIAL 
CHEMOEMBOLIZATION FOR 
RECURRENT HEPATOCELLULAR 
CARCINOMA
G.-H. Liu, F. Shen and M.-C. Wu
Eastern Hepatobiliary Surgery Hospital, Second Military 
Medical University, 225 Changhai Road, Shanghai, 
200438, China
Objective: To evaluate the long-term result of transarterial 
chemoembolization for recurrent hepatocellular carcinoma 
(HCC).
Methods: From November 2005 to May 2010, a total of 976 
recurrent hepatocellular carcinoma who initially underwent 
curative resection were retrospectively studied. Recurrent 
HCC was treated by repeat hepatectomy (Re-He, n = 200), 
radiofrequency ablation (RFA, n = 219), or transarterial che-
moembolization (TACE, n = 557).
Results: TACE-treated patients had more recurrent tumors, 
larger primary tumors, and shorter interval of time-to-recur-
rence (TTR) than the other groups. The overall 1-, 2-, 3-, and 
4-year post-recurrence survival rates were 82.2, 61.6, 48.1%, 
and 35.5%, respectively, in the TACE group. Multivariate 
analysis identifi ed AFP ≥ 20 ng/ml (HR = 1.63, 95%CI 1.17–
2.25) at recurrence, GGT ≥ 64 u/L (HR = 1.69, 95%CI: 
1.23–2.32) at recurrence, recurrent tumor number ≥3 (HR = 
1.57, 95%CI: 1.11–2.21), recurrent tumor size ≥5 cm 
(HR = 1.88, 95%CI: 1.13–3.14), primary tumor size ≥5 cm 
(HR = 1.42, 95%CI: 1.02–2.00), and TTR ≤3 months (HR = 
1.53, 95%CI: 1.02–2.28) as signifi cant prognostic factors for 
overall post-recurrence survival in the TACE group.
Conclusions: 1. Patients with multifocal/suspected multifo-
cal intrahepatic recurrence could benefi t from TACE. 2. 
TACE is a optimal modality for unresectable HCC with 
recurrent tumor size ≥5 cm or poor liver function reserve. 3. 
For the patients with long-term elevated AFP levels (in the 
exclusion of active hepatitis) but without typical imaging 
features of recurrent nodular in liver remnant, TACE has a 
unique value both in diagnosis and treatment.
PL-16
YTTRIUM-90 MICROSPHERES OR 
ELUDING BEADS
T. W. T. Leung
Comprehensive Oncology Centre, Hong Kong Sanatorium 
and Hospital, Hong Kong, China
Drug eluting beads (DEB) and ytrrium-90 microspheres 
selective internal radiation treatment (SIRT) are both new 
modalities for the treatment of localized unresectable hepa-
tocellular carcinoma (HCC). From non-randomized studies 
comparing conventional transarterial chemoembolization 
(TACE) with either DEB or SIRT, it was found that the newer 
modalities had more objective response, better tolerance and 
fewer sessions of treatment. Survival duration appeared to 
be better for DEB or SIRT compared with TACE in retro-
spective studies. With higher objective response rates for 
DEB and SIRT, some patients can be downstaged for resec-
tion after treatment, which is seldom seen for TACE. There 
is no prospective randomized study comparing DEB and 
SIRT. DEB is easier to deliver and the drugs are ready made 
for use. However, the particle size is larger for DEB than 
SIRT, thus has more embolizing effect. DEB also requires 
repeated treatment for optimum benefi t. As for SIRT, it 
requires a pre-treatment simulation procedure for patient 
selection. About 10% patients are not suitable for SIRT due 
to poor tumor to normal ratio or high lung shunting after 
pre-treatment simulation. Due to smaller particle size and 
less embolizing effect, SIRT can safely be given even for 
patients with portal vein thrombosis. However, the smaller 
particles might make it easier to shunt to the lungs or non-
tumorous liver parenchyma. SIRT appears to be more effec-
tive for larger tumors and does not have the issue of 
chemotherapy resistance.
